AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Status:
Not yet recruiting
Trial end date:
2023-11-08
Target enrollment:
Participant gender:
Summary
This is a modular dose confirmation and expansion study. The core study design is to assess
the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants
with either r/r PTCL or r/r cHL and to confirm the safety profiles and PK in these
populations. Module 1 of this study will evaluate the efficacy, safety, and tolerability of
AZD4573 monotherapy in participants with r/r PTCL or r/r cHL. If AZD4573 monotherapy is found
to have promising anti-tumour efficacy in Module 1, an AZD4573 monotherapy Phase II expansion
may be added via a substantial protocol amendment.